I
ILIAS Biologics
Developing engineered exosomes to deliver therapeutic proteins for treating life-threatening diseases
About ILIAS Biologics
ILIAS Biologics, Inc. is a biotechnology company specializing in the development of engineered exosomes, which are tiny vesicles that can deliver therapeutic proteins to intracellular pathways that are otherwise difficult to target. The company operates in the biopharmaceutical market and primarily serves clients in the healthcare and medical research sectors. ILIAS Biologics employs a proprietary platform technology to load large therapeutic payloads inside exosomes, aiming to treat life-threatening and hard-to-treat diseases such as inflammatory bowel disease (IBD) and acute kidney injury (AKI). The company generates revenue through research and development contracts, grants, and strategic partnerships with other biotech firms and research institutions. By leveraging open innovation, ILIAS Biologics is expanding its global network of research and business alliances to maximize its potential in developing novel exosome-based therapies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2020 | $21M | $82M | HB Investment · Timefolio Asset Management · Meritz Securities · Daishin Securities | — |
| SERIES AEquity / VC | May 2018 | $17M | $68M | Undisclosed | — |
Growth signals
Latest recorded traffic for ILIAS Biologics is 3.1K monthly website visits, down 26.2% over the last three months. ILIAS Biologics's team grew 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ILIAS Biologics in the Daejeon ecosystem
The ILIAS Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
HB Investment- TMTimefolio Asset Management
Meritz Securities
Daishin Securities- HSHanyang Securities
Kiwoom Securities
Dev Sisters Ventures
Daedeok Venture Partners
Asset One
Other known investors1 additional known investor
KAIST ILP
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ILIAS Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ILIAS Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






